Amur Minerals Advances Toward Reverse Takeover in Healthcare Sector

Amur Minerals has recently announced its status as an AIM Rule 15 cash shell and is making progress toward completing a Reverse Takeover (RTO), a strategic move aligning with AIM Rule 14. On January 25, 2024, Amur entered into a preliminary agreement to acquire a UK-based pharmaceutical company, identified as the Target. This company has innovated a drug delivery technology aimed at enhancing the effectiveness of cancer treatments for solid tumors by enabling the localized administration of chemotherapy.

In exchange for the complete issued share capital of the Target, Amur will issue new ordinary shares. This proposed acquisition is set to constitute an RTO, contingent upon several factors including successful due diligence in financial, legal, and technical aspects, the negotiation and finalization of a Sale and Purchase Agreement (SPA), the publication of an AIM Admission Document, and the approval from Amur's shareholders in a forthcoming general meeting.

Amur is actively progressing with the necessary procedures to finalize the RTO process and anticipates the publication of the AIM Admission Document by the end of April 2024. Consequently, trading of the Company’s shares will be suspended until the document is made available.

However, it's important to note that the completion of this RTO, or any potential RTO, cannot be guaranteed at this point.